Trials / Completed
CompletedNCT00771147
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
Prospective Open-label Non-interventional, Non-controlled Multi Observational and Pharmaco-economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar® Treatment Under Daily-life Treatment Conditions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 71 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®. |
Timeline
- Start date
- 2008-06-01
- Completion
- 2010-11-01
- First posted
- 2008-10-13
- Last updated
- 2012-06-15
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00771147. Inclusion in this directory is not an endorsement.